Vaccines
Bavarian Nordic has established a well respected position in the
biodefence space and is further utilizing its core competencies
with respect to developing and producing viral vaccine platforms
(MVA-BN® and other Poxvirus-vectors) for a wide variety of
applications in biotechnology and medicine.
The company designs, constructs, develops and manufactures viral
vaccines for research, clinical and commercial applications.
Our regulatory and clinical development teams have broad
competencies in designing and implementing clinical programs (Phase
I-III) for therapeutic and prophylactic vaccines covering smallpox
(IMVAMUNE® - phase II completed), HIV (phase I/II), breast
cancer (phase I/II), prostate cancer (PROSTVAC™ - phase II
completed) and Measles/RSV (phase I).
Bavarian Nordic's manufacturing facility in Denmark is the
world's only dedicated facility for the industrial manufacturing of
MVA-based vaccines. The facility has been designed and constructed
to fulfil the strictest European and US requirements for the
production of sterile vaccines.
We have worked with the US Government in the field of
smallpox for over 10 years. In June 2007, the US Government
solidified this partnership by awarding Bavarian Nordic a 5-year
contract (RFP-3) to deliver up to a total of 80 million doses
of a new safe and effective MVA-based third generation smallpox
vaccine, IMVAMUNE®.
Bavarian Nordic is cooperating with other government agencies
around the world in the biodefence space.
